Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Bristol-Myers Squibb said it would continue to assess trial operations. Lilly and Roche said that the Phase II/III DIAN-TU trial of their amyloid beta-targeting drugs - gantenerumab and ...

Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to the career path of his predecessor, Anat Ashkenazi, who also spent two ...

Shares of Eli Lilly & Co. LLY shed 0.02% to $923.54 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.13% to 5,633.09 ...

Eli Lilly And Co (LLY) stock saw a decline, ending the day at $912.75 which represents a decrease of $-33.56 or -3.55% from the prior close of $946.31. The stock opened at $941.16 and touched a low of ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Jim Cramer’s best stocks for investors. In a recent episode of Mad Money, Jim Cramer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...